1-9 of 9
Matthias Weiss
Close
Sort by
Journal Articles

Recombinant Human Diamine Oxidase Against Histamine Induced Shock - Implications for Mast Cell Activation Syndrome

Matthias Weiss-Tessbach, Birgit Reiter, Felix Kosta, Martin Murauer, Elisabeth Gludovacz, Thomas Böhm, Bernd Jilma, Marlene Rager-Resch
Journal: Blood
Blood (2023) 142 (Supplement 1): 3914.
https://doi.org/10.1182/blood-2023-185090
Published: 2023
Journal Articles

Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

Brad S. Kahl, Fangxin Hong, Christopher Peterson, Lode J. Swinnen, Thomas M. Habermann, Stephen J Schuster, Matthias Weiss, Paul A S Fishkin, W. Christopher Ehmann, Timothy S. Fenske, Michael E. Williams
Journal: Blood
Blood (2021) 138 (Supplement 1): 815.
https://doi.org/10.1182/blood-2021-152976
Published: 2021
Journal Articles

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Samuel Rubinstein, MD, Ryan C. Lynch, MD, Aakash Desai, MD, Catherine Stratton, MPH, Alokkumar Jha, PhD, Ziad Bakouny, MD MSc, Andrew Schmidt, MD, R. Alejandro Sica, MD, Divaya Bhutani, MD, Dimpy P. Shah, MD PhD, Sarah A Wall, MD, Gary H. Lyman, MD, Nicole M. Kuderer, MD MSc, Matthias Weiss, MD PhD, Jeremy L. Warner, MD MS, Keith E. Stockerl-Goldstein, MD, Ruben Mesa, MD, Michael A. Thompson, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–30.
https://doi.org/10.1182/blood-2020-141937
Published: 2020
Journal Articles

Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma

Clinical Trials & Observations
A. Keith Stewart, Susanna Jacobus, Rafael Fonseca, Matthias Weiss, Natalie S. Callander, Asher A. Chanan-Khan, S. Vincent Rajkumar
Journal: Blood
Blood (2015) 126 (11): 1294–1301.
https://doi.org/10.1182/blood-2014-12-613927
Published: 2015
Includes: Supplemental data
Journal Articles

Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group

Sagar Lonial, M.D., Susanna Jacobus, Matthias Weiss, MD, PhD, Rafael Fonseca, MD, Madhav V. Dhodapkar, MD, S. Vincent Rajkumar, MD
Journal: Blood
Blood (2013) 122 (21): 3174.
https://doi.org/10.1182/blood.V122.21.3174.3174
Published: 2013
Journal Articles

Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials.

Matthias Weiss, Susanna Jacobus, Rafat Abonour, Kenneth C. Anderson, Bart Barlogie, MD, Natalie Callander, MD, Edward J. Gorak, Antje Hoering, Robert C. Kane, Michael S Katz, Jeffrey Matous, Glenn M. Mills, MD, FACP, James Omel, Robert Z. Orlowski, M.D., Ph.D., S. Vincent Rajkumar, Paul G. Richardson, MD, LeeAnn Jensen, Richard F. Little, Morie A Gertz, Nikhil C. Munshi, MD
Journal: Blood
Blood (2012) 120 (21): 3165.
https://doi.org/10.1182/blood.V120.21.3165.3165
Published: 2012
Journal Articles

Bendamustine + Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Wisconsin Oncology Network (WON) Study

Julie E. Chang, MD, Chong Zhang, KyungMann Kim, PhD, Rachel Kirby, Lynn Volk, Jae Werndli, Ronald S. Go, MD, Matthias Weiss, MD, PhD, Jules H. Blank, MD, Michael A. Thompson, MD, PhD, John P. Farnen, MD, FACP, Craig E. Cole, MD, Ali W. Bseiso, MBBS, Michael Volk, MD, Gerald Bayer, MD, Tim Wassenaar, MD, Patrick Mansky, MD, Anne Traynor, Timothy S. Fenske, MD, Brad S. Kahl, M.D.
Journal: Blood
Blood (2012) 120 (21): 3647.
https://doi.org/10.1182/blood.V120.21.3647.3647
Published: 2012
Journal Articles

Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group

Sagar Lonial, MD, Susanna Jacobus, Matthias Weiss, Rafael Fonseca, MD, Madhav V. Dhodapkar, MD, S. Vincent Rajkumar, MD
Journal: Blood
Blood (2012) 120 (21): 4079.
https://doi.org/10.1182/blood.V120.21.4079.4079
Published: 2012
Journal Articles

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Matthias Weiss, MD, PhD, Susanna Jacobus, MS, Lynne I Wagner, PhD, David Cella, PhD, Michael S Katz, BS., MBA, Vincent Rajkumar, MD, Rafael Fonseca, MD
Journal: Blood
Blood (2011) 118 (21): 4184.
https://doi.org/10.1182/blood.V118.21.4184.4184
Published: 2011